Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) had its price target boosted by HC Wainwright from $25.00 to $60.00 in a report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Longboard Pharmaceuticals’ Q4 2023 earnings at ($0.52) EPS, FY2023 earnings at ($2.28) EPS, […]
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its.